Company Description
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.
The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.
It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction.
In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors.
Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson.
The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001.
The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
| Country | Israel |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Motti Farbstein |
Contact Details
Address: 26 Ben Gurion Street Ramat Gan, 5257346 Israel | |
| Phone | 972 3 924 1114 |
| Website | canfite.com |
Stock Details
| Ticker Symbol | CANF |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001536196 |
| CUSIP Number | 13471N201 |
| ISIN Number | US13471N4097 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Motti Farbstein | Chief Executive Officer, Chief Financial Officer, Financial and Operating Officer |
| Dr. Pnina Fishman Ph.D. | Founder, Chief Scientific Officer and Executive Chairperson |
| Dr. Sari Fishman Ph.D. | Vice President of Business Development |
| Dr. Stephen A. Harrison FACP, M.D. | Member of Clinical Advisory Board and Consulting Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2026 | 6-K | Report of foreign issuer |
| Apr 23, 2026 | 6-K | Report of foreign issuer |
| Apr 3, 2026 | EFFECT | Notice of Effectiveness |
| Apr 3, 2026 | 424B3 | Prospectus |
| Mar 31, 2026 | EFFECT | Notice of Effectiveness |
| Mar 31, 2026 | EFFECT | Notice of Effectiveness |
| Mar 31, 2026 | UPLOAD | Filing |
| Mar 31, 2026 | F-3 | Filing |
| Mar 31, 2026 | POS AM | Post-Effective amendments for registration statement |
| Mar 31, 2026 | POS AM | Post-Effective amendments for registration statement |